Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of [14C]-DNL343 in Healthy Males
NCT06281158Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DNL343 in amyotrophic lateral sclerosis (ALS), sponsored by Denali Therapeutics Inc. Primary endpoints: Area Under the Curve from Time Zero to Infinity at 28 days, Area Under the Curve from Time Zero to the Last Measurable Concentration at 28 days and 6 more. Started Mar 2024; status: completed.
02
Drugs
DNL343
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06281158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281158.